Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 30,780

Document Document Title
WO/2022/232332A1
The present disclosure provides compounds useful for the inhibition of KRAS G12D. The compounds have a general Formula I: (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical composition...  
WO/2022/228576A1
A protein regulator-targeted compound and an application thereof. The compound is a compound represented by formula Ia, Ib or Ic. The compound has a good inhibition effect and protein degradation effect on a KRAS_G12D mutant.  
WO/2022/228413A1
Disclosed in the present invention are an RIPK1 inhibitor for inhibiting programmed cell death and a preparation method therefor. The RIPK1 inhibitor of the present invention is as represented by general formula I, wherein X, Y, Z, L, R1...  
WO/2022/225914A1
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.  
WO/2022/222730A1
Disclosed in the present invention are a compound with mother nucleus of 3-phenyl-1,2,4-oxadiazole, a preparation method therefor and an application thereof. The compound with mother nucleus of 3-phenyl-1,2,4-oxadiazole provided in the p...  
WO/2022/224924A1
The present invention addresses the problem of providing: a nitrogen-containing heteroaryl compound which exhibits excellent bactericidal and anti-bacterial activity and excellent safety and which can be synthesized in an industrially ad...  
WO/2022/223039A1
An SOS1 degrader, a preparation method therefor and an application thereof. Specifically, the present invention relates to a compound of formula I: S-L-E (I), wherein S is a small molecule compound capable of inhibiting the activity of a...  
WO/2022/226203A1
Disclosed herein are compounds that inhibit 3C-like protease and inhibit replication of viruses, including SARS-CoV-2. Also disclosed herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds, e....  
WO/2022/218289A1
This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for t...  
WO/2022/219123A1
The present invention relates to ureal derivatives of formula (I) and pharmaceutical compositions comprising such derivatives for use in the treatment of uveal melanoma.  
WO/2022/221194A1
Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).  
WO/2022/219412A1
Disclosed herein, in part, is a compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I: (I) wherein X1 is selected from the group consisting of linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10...  
WO/2022/189856A9
This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising...  
WO/2022/216946A1
The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.  
WO/2022/216627A1
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...  
WO/2022/214053A1
A compound of formula (I) as a USP1 inhibitor or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the pharmaceutically acceptable salt thereof, and the use thereof in the prevention or t...  
WO/2022/214606A1
The present invention relates to compounds of formula (I) or salts, solvates, cocrystals, tautomers, or mixtures thereof. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds. Moreover, the ...  
WO/2022/216945A1
The present disclosure provides compounds, such as compounds of Formula III, and compositions that are MCL1 inhibitors.  
WO/2022/207404A1
The application relates to substituted pyrrole carboxamide derivatives of formula (I) which modulate the activity of cycle 7-related protein kinase (Cdc7). The compounds of this invention are therefore useful in treating diseases related...  
WO/2022/207752A1
A compound comprising the formula (I), wherein each X1 is independently selected from C, N, O and S; each Y is independently selected from C and N; Z1 is independently selected from C and N; each X1 may independently be unsubstituted, or...  
WO/2022/206797A1
Compounds of formula A, a method for using said compounds as an EGFR inhibitor, and a pharmaceutical composition comprising said compounds. The compounds can be used to treat, prevent or ameliorate diseases or conditions such as cancers ...  
WO/2022/207494A1
The present invention relates to 3-(hetero)aryl-5-chlorodifluoromethyl-1,2,4-oxadiazole compounds as well as the uses thereof for controlling harmful microorganisms, in particular phytopathogenic fungi, in crop protection.  
WO/2022/212489A1
Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammato...  
WO/2022/212194A1
Compounds of formula (I), wherein the variable substituents are defined herein.  
WO/2022/208356A1
Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with P-lactamase inhibitor...  
WO/2022/208454A1
The present disclosure relates to novel N2-phenylpyrimidine-2,4-diamine compounds, method for preparing the same, and pharmaceutical composition or health functional food for the prevention or treatment of cancer, containing the same as ...  
WO/2022/204902A1
A benzothiazinone derivative substituted with trifluoromethyl at 6-position, and a preparation method therefor and the use thereof. A series of compounds are obtained by means of changing the benzene ring of the benzothiazinone backbone,...  
WO/2022/206447A1
The present disclosure relates to an injectable lurasidone suspension and a preparation method thereof, and in particular to an irregular form of a lurasidone solid and a pharmaceutical composition thereof. The present disclosure also re...  
WO/2022/212815A1
Described are 6-aryl quinazolin-4(3H)-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treat...  
WO/2022/207462A1
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.  
WO/2022/206725A1
Compounds of general Formula I, II, III, IV, V and their pharmaceutically acceptable salts, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are synthesis, ...  
WO/2022/211518A1
The present invention pertains to a novel compound and a use thereof in treating psoriasis, asthma, or systemic lupus erythematosus. A pharmaceutical composition containing the novel compound of the present invention can not only control...  
WO/2022/207665A1
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.  
WO/2022/206010A1
Disclosed in the present invention is a simple preparation method for isoxazolines, comprising: using aldehyde, p-toluenesulfonyl hydrazide, olefin, and tert-butyl nitrite as a substrate, using copper chloride as a catalyst, using tetram...  
WO/2022/211060A1
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease associated with ABHD6, which contains a compound having an ABHD6-inhibiting activity as an active ingredient. A compound repre...  
WO/2022/208262A1
The invention relates to compounds of Formula I and pharmaceutically acceptable salts thereof wherein R1, R2, R3, p, q, q' and Ring A are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating corona...  
WO/2022/203246A1
The present specification relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising same.  
WO/2022/202538A1
A compound which is represented by formula (1). The present invention provides a compound which has high refractive index and excellent polymerizability, and which is useful as a starting material for an optical material, and the like. (...  
WO/2022/203399A1
The present invention relates to an antagonist of an adenosine A2A receptor, a pharmaceutical composition containing same for preventing or treating adenosine A2A receptor-related disease (for example cancer), and a method for treating a...  
WO/2022/200594A1
The present invention relates to a method for preparing an enantiomerically enriched form of 2-[2-(2-chlorothiazol-5-yl)-2- hydroxy-ethyl]sulfanyl-6-hydroxy-3-methyl-5-phenyl-pyrimidin -4-one of the formula (I) by hydrogenation of 2-[2-(...  
WO/2022/201097A1
Provided herein are compounds and pharmaceutical compositions useful for treating diseases or disorders mediated by the TRPV1 receptor. The present invention also provides methods for treating ocular diseases or disorders by administerin...  
WO/2022/201162A1
The present invention provides compounds and pharmaceutical compositions comprising thereof. Further, methods for treating or preventing development of a RNF4 related disorder in a subject in need thereof are also provided.  
WO/2022/203332A1
The present invention provides a novel compound having a cyclohexyl-(alkyl or cycloalkyl-substituted)ethylene-amino-heteroaryl moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical co...  
WO/2022/204683A1
Disclosed herein are quinazolinyl compounds, compositions, and methods of use thereof. The compounds may be used in the treatment of kinase-related disorders (including cancer, autoimmune disease, and Duchenne muscular dystrophy).  
WO/2022/202864A1
The present invention relates to: a compound, or a pharmacologically acceptable salt thereof, that has GLP-1 receptor agonist activity and that is useful as an agent for treating or preventing diseases involving the GLP-1 receptors; and ...  
WO/2022/199661A1
Provided is compound of Formula (Y) or Formula (A) or pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of GLP-1 receptor, a pharmaceutical composition comprising...  
WO/2022/200785A1
There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R6, X, Y, Z, Y1, Y2, Y3 and Y4 have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, i...  
WO/2022/199611A1
Provided is a heterocycle substituted ketone derivative, the structure of which is as shown in formula (I). Further provided are a pharmaceutically acceptable salt of the derivative, a stereoisomer thereof, a pharmaceutical composition a...  
WO/2022/199815A1
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 2 (LPA2), particularly the invention relates to compounds that are 8-cyclo-substituted quinazoline derivatives, methods of prepar...  
WO/2022/204227A1
The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including h...  

Matches 701 - 750 out of 30,780